| Citation: |
LIU Leheng, ZHAO Yan, ZHANG Qian, WANG Danni. Progress of Intestinal Flora Disorder and Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2019, 46(12): 1136-1140. DOI: 10.3971/j.issn.1000-8578.2019.19.0462
|
Hepatocellular carcinoma (HCC) is a common therioma of digestive system. The occurrence of HCC involves many aspects, such as environment, metabolism and genetic factors. In recent years, it has been found that intestinal flora imbalance is also an important factor in the occurrence of HCC. When intestinal flora disorders occur, the intestinal mucosal barrier can be destroyed, bacterial translocation and endotoxemia can cause chronic inflammatory response of hepatocytes. Long-term and chronic changes of intestinal flora metabolites such as short-chain fatty acids and bile acids also play a role in promoting HCC. At present, a variety of methods to improve intestinal flora disorders have shown a bright future in the treatment of HCC. This article reviews the mechanisms of intestinal flora-induced HCC and the preventive and therapeutic measures against intestinal flora imbalance.
| [1] |
Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma[J]. Gut, 2018, 67(2): 380-388. doi: 10.1136/gutjnl-2017-315068
|
| [2] |
Sebastián Domingo JJ, Sánchez Sánchez C. From the intestinal flora to the microbiome[J]. Rev Esp Enferm Dig, 2018, 110(1): 51-56. http://d.old.wanfangdata.com.cn/Periodical/sjkxjs-zyxdh201707017
|
| [3] |
Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg[J]. Hepatol Int, 2018, 12(Suppl1): 24-33. http://cn.bing.com/academic/profile?id=414b2f429d13d238ea29d928b81b66d7&encoded=0&v=paper_preview&mkt=zh-cn
|
| [4] |
Chu H, Duan Y, Yang L, et al. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease[J]. Gut, 2019, 68(2): 359-370. doi: 10.1136/gutjnl-2018-316307
|
| [5] |
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(2): 111-128. doi: 10.1038/nrgastro.2017.119
|
| [6] |
Kim M, Friesen L, Park J, et al. Microbial metabolites, short-chain fatty acids, restrain tissue bacterial load, chronic inflammation, and associated cancer in the colon of mice[J]. Eur J Immunol, 2018, 48(7): 1235-1247. doi: 10.1002/eji.201747122
|
| [7] |
Rainer F, Horvath A, Sandahl TD, et al. Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation[J]. Aliment Pharmacol Ther, 2018, 47(5): 657-664. doi: 10.1111/apt.14474
|
| [8] |
Orci L A, Lacotte S, Delaune V, et al. Effects of the gut-liver axis on ischemia-mediated hepatocellular carcinoma recurrence in the mouse liver[J]. J Hepatol, 2018, 68(5): 978-985. doi: 10.1016/j.jhep.2017.12.025
|
| [9] |
Sepehri Z, Kiani Z, Kohan F, et al. Toll like receptor 4 and hepatocellular carcinoma; A systematic review[J]. Life Sci, 2017, 179: 80-87. doi: 10.1016/j.lfs.2017.04.025
|
| [10] |
Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539. doi: 10.1038/nrgastro.2017.72
|
| [11] |
Weber SN, Bohner A, Dapito DH, et al. TLR4 deficiency protects against hepatic fibrosis and diethylnitrosamine-induced pre-carcinogenic liver injury in fibrotic liver[J]. PLoS One, 2016, 11(7): e0158819. doi: 10.1371/journal.pone.0158819
|
| [12] |
Jing YY, Han ZP, Sun K, et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide[J]. BMC Med, 2012, 10: 98. doi: 10.1186/1741-7015-10-98
|
| [13] |
Xu D, Huang Y, Wang J. Gut microbiota modulate the immune effect against hepatitis B virus infection[J]. Eur J Clin Microbiol Infect Dis, 2015, 34(11): 2139-2147. doi: 10.1007/s10096-015-2464-0
|
| [14] |
Yang R, Xu Y, Dai Z, et al. The immunologic role of gut microbiota in patients with chronic HBV infection[J]. J Immunol Res, 2018, 2018: 2361963. http://cn.bing.com/academic/profile?id=dfec61860659c44fee4a67558931cb01&encoded=0&v=paper_preview&mkt=zh-cn
|
| [15] |
Chou HH, Chien WH, Wu LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112(7): 2175-2180. doi: 10.1073/pnas.1424775112
|
| [16] |
Chen T, Kim CY, Kaur A, et al. Dietary fibre-based SCFA mixtures promote both protection and repair of intestinal epithelial barrier function in a Caco-2 cell model[J]. Food Funct, 2017, 8(3): 1166-1173. doi: 10.1039/C6FO01532H
|
| [17] |
Ahmed M. Non-alcoholic fatty liver disease in 2015[J]. World J Hepatol, 2015, 7(11): 1450-1459. doi: 10.4254/wjh.v7.i11.1450
|
| [18] |
Weitkunat K, Stuhlmann C, Postel A, et al. Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice[J]. Sci Rep, 2017, 7(1): 6109. doi: 10.1038/s41598-017-06447-x
|
| [19] |
Ortega JF, De Conti A, Tryndyak V, et al. Suppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein[J].Oncotarget, 2016, 7(17): 24339-24347. http://cn.bing.com/academic/profile?id=631a8df566d0c4cfe2e0bf0b5713584b&encoded=0&v=paper_preview&mkt=zh-cn
|
| [20] |
Gallage S, Kotsiliti E, Heikenwalder M. When Soluble Fibers Meet Hepatocellular Carcinoma: The Dark Side of Fermentation[J].Cell Metab, 2018, 28(5): 673-675. doi: 10.1016/j.cmet.2018.10.009
|
| [21] |
Yamada S, Takashina Y, Watanabe M, et al. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice[J]. Oncotarget, 2018, 9(11): 9925-9939. http://cn.bing.com/academic/profile?id=f616a6685569bff88484c32b77b1747d&encoded=0&v=paper_preview&mkt=zh-cn
|
| [22] |
Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment[J]. Biochim Biophys Acta Mol Basis Dis, 2017, 864(2): 607-617. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=b31bc8074b2784e1cfde27f25f7ce47b
|
| [23] |
Cariello M, Peres C, Zerlotin R, et al. Long-term administration of nuclear bile acid receptor FXR agonist prevents spontaneous hepatocarcinogenesis in Abcb4(-/-) Mice[J]. Sci Rep, 2017, 7(1): 11203. doi: 10.1038/s41598-017-11549-7
|
| [24] |
Kainuma M, Takada I, Makishima M, et al. Farnesoid X receptor activation enhances transforming growth factor β-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells[J]. Int J Mol Sci, 2018, 19(7): pii:E1898. doi: 10.3390/ijms19071898
|
| [25] |
Genda T, Kondo T, Sugiura S, et al. Bacterial fermentation of water-soluble cellulose acetate raises large-bowel acetate and propionate and decreases plasma cholesterol concentrations in rats[J].J Agric Food Chem, 2018, 66(45): 11909-11916. doi: 10.1021/acs.jafc.8b04093
|
| [26] |
Li J, Sung CY, Lee N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J]. Proc Natl Acad Sci U S A, 2016, 113(9): E1306-E1315. doi: 10.1073/pnas.1518189113
|
| [27] |
Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(9): 508-516. doi: 10.1038/nrgastro.2016.98
|
| [28] |
Miura K, Ishioka M, Minami S, et al. Toll-like receptor 4 on macrophage promotes the development of steatohepatitis-related hepatocellular carcinoma in mice[J]. J Biol Chem, 2016, 291(22): 11504-11517. doi: 10.1074/jbc.M115.709048
|
| [29] |
Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications[J]. World J Gastroenterol, 2019, 25(8): 888-908. doi: 10.3748/wjg.v25.i8.888
|
| [30] |
Menshawy A, Mattar O, Barssoum K, et al. Safety and efficacy of rifaximin in prophylaxis of spontaneous bacterial peritonitis: a systematic review and meta-analysis[J]. Curr Drug Targets, 2019, 20(4): 380-387. doi: 10.2174/1389450119666180924145156
|
| [31] |
Elfert A, Abo Ali L, Soliman S, et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J]. Eur J Gastroenterol Hepatol, 2016, 28(12): 1450-1454. doi: 10.1097/MEG.0000000000000724
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: